OR WAIT null SECS
Novartis provides its second US university with Bexsero for the treatment of meningitis B.
Novartis reported that its meningococcal serogroup B (MenB) vaccine, Bexsero (Meningococcal Group B Vaccine), will be used as part of a vaccination program at the University of California Santa Barbara (UCSB). In the last three months, FDA has approved the use of Bexsero twice in response to MenB outbreaks at US college campuses. More than 5,000 students were vaccinated at Princeton University and 20,000 students will be offered vaccination at UCSB.
Bexsero is the only licensed broad coverage vaccine approved in Europe, Canada, and Australia to help protect against invasive meningococcal disease caused by serogroup B. It was approved for use in the US under a treatment Investigational New Drug designation.